ASCO 2025 | TroFuse-020: sacituzumab tirumotecan in pre-treated cervical cancer
Ritu Salani, MD, MBA, University of California Los Angeles, Los Angeles, CA, discusses the design of the Phase III TroFuse-020/GOG-3101/ENGOT-cx20 trial (NCT06459180) of sacituzumab tirumotecan monotherapy versus treatment of physician’s choice in patients with recurrent or metastatic cervical cancer previously treated with platinum-based chemotherapy and checkpoint inhibitors. The study aims to evaluate overall survival as the primary endpoint, with secondary measures including progression-free survival, response rates, safety, and quality-of-life outcomes. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
